The trial is being performed under the direction of Drs. Filip Janku, M.D. and Gerald Falchook, M.D. as Co-Principal Investigators. Dr. Janku is Assistant Professor in the Department of Investigational Therapeutics at MD Anderson Cancer Center, Houston, TX, and Dr. Falchook is Director, Drug Development Program, Sarah Cannon Research Institute, Denver, CO. Both Drs. Janku and Falchook are experts in early phase cancer clinical research studies of novel new agents.
FF-10502 is an antimetabolite anti-cancer drug that inhibits DNA synthesis. It has demonstrated preclinical activity against tumors resistant to gemcitabine therapy, a common anti-cancer agent used in the treatment of lymphoma and advanced ovarian, metastatic breast, locally advanced and metastatic lung and pancreatic cancers.
Gerald Falchook said: "We are very excited to be collaborating with FPHU and Strategia on this important clinical trial in patients with advanced solid tumors and lymphomas.
"This drug may provide another alternative for patients who have failed conventional chemotherapeutic approaches, and we are pleased to be furthering this research at our institution."
Strategia chief medical officer Thomas Myers said: "Strategia is pleased to initiate this important clinical trial for FPHU with these two esteemed investigators at such prestigious institutions.
"FF-10502 has shown activity against important gemcitabine-resistant cancers, and we are now poised to bring this investigational new drug to patients in the clinical setting."